Amadeus Capital Partners has bought a stake in the Amgen and Illumina-backed company through a secondary transaction, valuing it at around $2.4bn.
Venture capital firm Amadeus Capital Partners has paid $24m to acquire shares in Oxford Nanopore, a UK-based DNA sequencing technology developer backed by corporates Amgen and Illumina, in a secondary transaction.
The deal valued Oxford Nanopore at roughly $2.4bn, according to the Telegraph, which said Amadeus had bought into the spinout this way after missing out on a previous round.
Spun out of University of Oxford in 2005, Oxford Nanopore is working on a genetic sequencing-derived analysis technology that can…
